Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Abstract:
Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

Cambridge, MA | Posted on January 3rd, 2008

"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer at Mersana. "Boyd brings diverse management experience and commercial expertise in areas important to Mersana at our stage of development. His skills complement those of our existing team very well, and we anticipate his strategic leadership will be of considerable value as we advance our pipeline."

Over the past 11 years Mr. Clarke has held the role of Chairman and Chief Executive Officer at several publicly-held biotechnology companies, most recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke led the company from a platform-based discovery operation to a clinical stage development company with multiple product candidates. As President and CEO of Aviron he oversaw the Biological Licensing Application (BLA) submission for the company's lead product and ultimately secured the sale of the vaccine company to MedImmune. He also served as President and CEO of US Bioscience. Mr. Clarke began his pharmaceutical career at Merck, where he held a series of increasingly responsible positions, including President of Pasteur Merieux MSD and Vice President of Merck Vaccines. He holds a Bachelor of Science degree and a Master of Arts degree from the University of Calgary. Mr. Clarke serves on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member of the Biotechnology Industry Association (BIO).

"Mersana's Fleximer(R) technology has the potential to create safer and more efficacious cancer drugs, and the promise of the technology is now being demonstrated in their ongoing clinical studies," stated Boyd Clarke. "I'm excited by the Company's prospects and am looking forward to participating in their continued growth as Chairman."

####

About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate, which is currently in Phase 1 clinical trials and several preclinical stage oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For more information, please click here

Contacts:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139

Tel: 617.498.0020
Fax: 617.498.0109

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Novel Rocket Design Flight Tested: New Rocket Propellant and Motor Design Offers High Performance and Safety October 23rd, 2014

MEMS & Sensors Technology Showcase: Finalists Announced for MEMS Executive Congress US 2014 October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014

Announcements

Nanoparticle technology triples the production of biogas October 23rd, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014

VDMA photonics steering committee with new members stronger than ever October 14th, 2014

Agar Scientific appoints Paul Balaş as new Technical Sales Manager October 3rd, 2014

PEN Inc. Chairman Scott Rickert Announces Company Vision, Product Priorities and Management Team: Webcast Highlights the Launch of PEN October 3rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE